Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Drug Profile

Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Alternative Names: Anti-CTFG RNAi therapy; Anti-VEGF sd-rxRNA; RXI-762; RXI-804; rxRNA®; rxRNAori®; sd-rxRNA®; Self-delivering RNAi compounds - RXi Pharmaceuticals

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RXi Pharmaceuticals Corporation
  • Developer RXi Pharmaceuticals; RXi Pharmaceuticals Corporation; University of Massachusetts Medical School
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; PDCD 1 protein inhibitors; RNA interference; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - CNS disorders; CNS disorders; Eye-Disorders; Respiratory tract disorders; Retinal disorders

Highest Development Phases

  • Preclinical Cancer
  • Research Skin disorders
  • No development reported CNS disorders; Eye-Disorders; Inflammation; Metabolic disorders; Obesity; Respiratory tract disorders; Retinal disorders; Rheumatoid arthritis
  • Discontinued Cytomegalovirus retinitis

Most Recent Events

  • 13 Nov 2017 RXi Pharmaceuticals Corporation and Gustave Roussy enter a research collaboration to develop sd-rxRNA compounds for Cancer
  • 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in USA (Intrathecal, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top